Literature DB >> 32813109

Vitreous levels of vascular endothelial growth factor, stromal cell-derived factor-1α, and angiopoietin-like protein 2 in patients with active proliferative diabetic retinopathy.

Ali Keles1, Kenan Sonmez2, Yasemin Ozdamar Erol3, Sema Nur Ayyıldız4, Elmas Ogus4.   

Abstract

PURPOSE: To determine the vitreous levels of vascular endothelial growth factor (VEGF), stromal cell-derived factor-1α (SDF-1α) and angiopoietin-like protein 2 (ANGPTL2) in patients with active proliferative diabetic retinopathy (PDR), and to ascertain their contribution on different clinical presentation of active PDR.
METHODS: This case-control study included 31 eyes with active PDR and 10 eyes with idiopathic macular hole (MH) (control group). Eyes with active PDR were divided into three subgroups: vitreous hemorrhage (VH), tractional retinal detachment (TRD) caused by active fibrovascular membrane (FVM), and coexistence of VH and TRD with FVM. Vitreous samples obtained during vitrectomy were analyzed for concentrations of VEGF, SDF-1α, and ANGPTL2.
RESULTS: Vitreous level of VEGF (2021 (168-6550) pg/ml vs 110.1 (74.5-236) pg/ml), SDF-1α (517 (194-1044) pg/ml vs 388 (320-535) pg/ml), and ANGPTL2 (725 (131-1590) ng/ml vs 196 (75.9-437) ng/ml) were significantly higher in eyes with active PDR than in control group (p < 0.001, p = 0.002, and p < 0.001, respectively). The concentrations of these meaditors in each active PDR subgroups were also significantly higher than control group (p < 0.05). The vitreous level of ANGPTL2 was significantly higher in eyes with TRD caused by FVM (1033 ± 401 ng/ml) than in eyes with VH (561 ± 237 ng/ml; p = 0.008).
CONCLUSION: High levels of SDF-1α, ANGPTL2 and particularly VEGF seem to be associated with PDR. Since the vitreous levels of ANGPTL2 tend to be higher in eyes with active fibrovascular tractional detachment, vitreous levels of this chemokine seem to be affected by the clinical presentation of vascularly active PDR eyes.

Entities:  

Keywords:  Angiopoietin-like protein 2; Proliferative diabetic retinopathy; Stromal cell–derived factor-1α; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2020        PMID: 32813109     DOI: 10.1007/s00417-020-04889-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  34 in total

Review 1.  Epidemiology of major eye diseases leading to blindness in Europe: a literature review.

Authors:  Elena Prokofyeva; Eberhart Zrenner
Journal:  Ophthalmic Res       Date:  2011-11-26       Impact factor: 2.892

Review 2.  Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).

Authors:  Anne Marie Byrne; D J Bouchier-Hayes; J H Harmey
Journal:  J Cell Mol Med       Date:  2005 Oct-Dec       Impact factor: 5.310

Review 3.  Positive and negative regulation of angiogenesis: from cell biology to the clinic.

Authors:  M S Pepper
Journal:  Vasc Med       Date:  1996       Impact factor: 3.239

Review 4.  Microvascular modifications in diabetic retinopathy.

Authors:  Jennifer T Durham; Ira M Herman
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

Review 5.  Diabetic retinopathy - ocular complications of diabetes mellitus.

Authors:  Martin M Nentwich; Michael W Ulbig
Journal:  World J Diabetes       Date:  2015-04-15

Review 6.  Vascular endothelial growth factors and angiogenesis in eye disease.

Authors:  A N Witmer; G F J M Vrensen; C J F Van Noorden; R O Schlingemann
Journal:  Prog Retin Eye Res       Date:  2003-01       Impact factor: 21.198

7.  First Incidence and Progression Study for Diabetic Retinopathy in Portugal, the RETINODIAB Study: Evaluation of the Screening Program for Lisbon Region.

Authors:  Marco Dutra Medeiros; Edgar Mesquita; Luís Gardete-Correia; Joaquim Moita; Victor Genro; Ana Luísa Papoila; Antónia Amaral-Turkman; João Filipe Raposo
Journal:  Ophthalmology       Date:  2015-09-15       Impact factor: 12.079

8.  Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England.

Authors:  Colin D Jones; Richard H Greenwood; Aseema Misra; Max O Bachmann
Journal:  Diabetes Care       Date:  2012-01-25       Impact factor: 19.112

Review 9.  The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.

Authors:  David I R Holmes; Ian Zachary
Journal:  Genome Biol       Date:  2005-02-01       Impact factor: 13.583

10.  Ocular Angiogenesis.

Authors:  Juliana L Dreyfuss; Ricardo J Giordano; Caio V Regatieri
Journal:  J Ophthalmol       Date:  2015-09-28       Impact factor: 1.909

View more
  4 in total

Review 1.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

2.  Effect of intravitreal ranibizumab on fibrovascular membranes in patients with proliferative diabetic retinopathy.

Authors:  Ze-Yu Liang; Yi-Peng Wang; Jing Li; Wen-Chao Yang; Yong-Fang Tu; Yue Zhang; Song Chen
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

3.  Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients.

Authors:  Yue Xu; Chi Xie; Yan Fang; Yan Yu; Cui Qiu
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

4.  Aqueous Humor Levels of Vascular Endothelial Growth Factor and Stromal Cell-Derived Factor-1α in Age-Related Macular Degeneration.

Authors:  Ali Keles; Yasemin Ozdamar Erol; Sema Nur Ayyildiz; Suleyman Korhan Karaman; Elmas Ogus
Journal:  Beyoglu Eye J       Date:  2021-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.